Discovery of a new series of imidazo1,2-apyridine compounds as selective c-Met inhibitors
文献类型：期刊论文
| 作者 | Liu Tongchao1; Peng Xia2; Ma Yuchi2; Ji Yinchun2; Chen Danqi2; Zheng Mingyue2; Zhao Dongmei1; Cheng Maosheng1; Geng Meiyu2; Shen Jingkang2 |
| 刊名 | ACTA PHARMACOLOGICA SINICA
 |
| 出版日期 | 2016 |
| 卷号 | 37期号:5页码:698-707 |
| 关键词 | RECEPTOR TYROSINE KINASE INVASIVE GROWTH SCATTER FACTOR CANCER DOCKING c-Met inhibitors hepatocyte growth factor receptor imidazo1,2-apyridine anticancer agents drug discovery |
| ISSN号 | 1671-4083 |
| 其他题名 | Discovery of a new series of imidazo1,2-apyridine compounds as selective c-Met inhibitors |
| 英文摘要 | Aim: Aberrant c-Met activation plays a critical role in cancer formation, progression and dissemination, as well as in development of resistance to anticancer drugs. Therefore, c-Met has emerged as an attractive target for cancer therapy. The aim of this study was to develop new c-Met inhibitors and elaborate the structure-activity relationships of identified inhibitors. |
| 资助项目 | [Foundation of China Postdoctoral Science] ; [National Natural Science Foundation of China] ; [National Science & Technology Major Project "Key New Drug Creation and Manufacturing Program" of China] ; [SA-SIBS Scholarship Program] |
| 语种 | 英语 |
| CSCD记录号 | CSCD:5700554 |
| 源URL | [http://ir.imr.ac.cn/handle/321006/148381]  |
| 专题 | 金属研究所_中国科学院金属研究所 |
| 作者单位 | 1.中国科学院金属研究所 2.中国科学院 |
| 推荐引用方式 GB/T 7714 | Liu Tongchao,Peng Xia,Ma Yuchi,et al. Discovery of a new series of imidazo1,2-apyridine compounds as selective c-Met inhibitors[J]. ACTA PHARMACOLOGICA SINICA,2016,37(5):698-707. |
| APA | Liu Tongchao.,Peng Xia.,Ma Yuchi.,Ji Yinchun.,Chen Danqi.,...&Xiong Bing.(2016).Discovery of a new series of imidazo1,2-apyridine compounds as selective c-Met inhibitors.ACTA PHARMACOLOGICA SINICA,37(5),698-707. |
| MLA | Liu Tongchao,et al."Discovery of a new series of imidazo1,2-apyridine compounds as selective c-Met inhibitors".ACTA PHARMACOLOGICA SINICA 37.5(2016):698-707. |
入库方式： OAI收割
来源：金属研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。